Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition

Current Drug Metabolism

Volumn 15, Issue 10, 2014, Pages 915-941

  Shi, Shaojun ^a   Li, Yunqiao ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Drug interactions; Drug transporters; Drug metabolizing enzymes; Genetic variations; Interplay; Mechanisms; Pharmacokinetics

Indexed keywords

ACYLTRANSFERASE; BILE SALT EXPORT PUMP; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CLARITHROMYCIN; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DOCETAXEL; DRUG METABOLITE; DRUG METABOLIZING ENZYME; DRUG TRANSPORTER; ELACRIDAR; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 4; ORGANIC CATION TRANSPORTER 2; PREGNANE X RECEPTOR; ROSUVASTATIN; SULFOTRANSFERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; DRUG; ISOENZYME;

APICAL MEMBRANE; AREA UNDER THE CURVE; ARTICLE; BASOLATERAL MEMBRANE; CELL LINE; COMPUTER MODEL; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INTESTINE CELL; LIVER CELL; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN FUNCTION; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE; ANIMAL; BIOTRANSFORMATION; ENZYME SPECIFICITY; METABOLISM; PHARMACOKINETICS; SPECIES DIFFERENCE;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; GASTROINTESTINAL ABSORPTION; HUMANS; ISOENZYMES; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY;

EID: 84932172189     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200216666150401110610     Document Type: Article

References (206)

1. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and Pglycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog., 1995, 13(3), 129-134.
2. Custodio, J. M.; Wu, C. Y.; Benet, L. Z. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev., 2008, 60(6), 717-733.
3. Zhang, L.; Zhang, Y.; Huang, S. M. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol. Pharm., 2009, 6(6), 1766-1774.
4. Pang, K. S.; Maeng, H. J.; Fan, J. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm., 2009, 6(6), 1734-1755.
5. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab., 2003, 4(5), 393-398.
6. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm., 2004, 277(1-2), 3-9.
7. Benet, L. Z. The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm., 2009, 6(6), 1631-1643.
8. International Transporter Consortium.; Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug Discov., 2010, 9(3), 215-236.
9. Fan, J.; Maeng, H. J.; Pang, K. S. Interplay of transporters and enzymes in the Caco-2 cell monolayer: I. effect of altered apical secretion. Biopharm. Drug Dispos., 2010, 31(4), 215-227.
10. Cummins, C. L.; Jacobsen, W.; Benet, L. Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 2002, 300(3), 1036-1045.
11. van Waterschoot, R. A.; Schinkel, A. H. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol. Rev., 2011, 63(2), 390-410.
12. Kivistö, K. T.; Niemi, M.; Fromm, M. F. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam. Clin. Pharmacol., 2004, 18(6), 621-626.
13. Endres, C. J.; Endres, M. G.; Unadkat, J. D. Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? Mol. Pharm., 2009, 6(6), 1756-1765.
14. Giacomini, K. M.; Huang, S. M. Transporters in drug development and clinical pharmacology. Clin. Pharmacol. Ther., 2013, 94(1), 3-9.
15. DeGorter, M. K.; Xia, C. Q.; Yang, J. J.; Kim, R. B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 249-273.
16. Zolk, O.; Fromm, M. F. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin. Pharmacol. Ther., 2011, 89(6), 798-805.
17. Zamek-Gliszczynski, M. J.; Kalvass, J. C.; Pollack, G. M.; Brouwer, K. L. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab. Dispos., 2009, 37(2), 386-390.
18. Gundert-Remy, U.; Bernauer, U.; Blömeke, B.; Döring, B.; Fabian, E.; Goebel, C.; Hessel, S.; Jäckh, C.; Lampen, A.; Oesch, F.; Petzinger, E.; Völkel, W.; Roos, P. H. Extrahepatic metabolism at the body's internal-external interfaces. Drug Metab. Rev., 2014, 46(3), 291-324.
19. Estudante, M.; Morais, J. G.; Soveral, G.; Benet, L. Z. Intestinal drug transporters: an overview. Adv. Drug Deliv. Rev., 2013, 65(10), 1340-1356.
20. Bruyère, A.; Declèves, X.; Bouzom, F.; Ball, K.; Marques, C.; Treton, X.; Pocard, M.; Valleur, P.; Bouhnik, Y.; Panis, Y.; Scherrmann, J. M.; Mouly, S. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. Mol Pharm., 2010, 7(5), 1596-1607.
21. Zhang, Q. Y.; Dunbar, D.; Ostrowska, A.; Zeisloft, S.; Yang, J.; Kaminsky, L. S. Characterization of human small intestinal cytochromes P-450. Drug Metab. Dispos., 1999, 27(7):804-809.
22. Zakeri-Milani, P.; Valizadeh, H. Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. Expert Opin. Drug Metab. Toxicol., 2014, 10(6), 859-871.
23. Zamek-Gliszczynski, M. J.; Chu, X.; Polli, J. W.; Paine, M. F.; Galetin, A. Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab. Dispos., 2014, 42(4), 650-664.
24. Arias, A.; Rigalli, J. P.; Villanueva, S. S.; Ruiz, M. L.; Luquita, M. G.; Perdomo, V. G.; Vore, M.; Catania, V. A.; Mottino, A. D. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity. Toxicology, 2014, 320 C, 46-55.
25. van de Wetering, K.; Burkon, A.; Feddema, W.; Bot, A.; de Jonge, H.; Somoza, V.; Borst, P. Intestinal breast cancer resistance protein (BCRP)/Bcrp1 and multidrug resistance protein 3 (MRP3)/Mrp3 are involved in the pharmacokinetics of resveratrol. Mol. Pharmacol., 2009, 75(4), 876-885.
26. Klatt, S.; Fromm, M. F.; König, J. Transporter-mediated drug-drug interactions with oral antidiabetic drugs. Pharmaceutics, 2011, 3(4), 680-705.
27. Lozano, E.; Herraez, E.; Briz, O.; Robledo, V. S.; Hernandez-Iglesias, J.; Gonzalez-Hernandez, A.; Marin, J. J. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed. Res. Int., 2013, 2013, 692071.
28. Rodrigues, A. D.; Lai, Y.; Cvijic, M. E.; Elkin, L. L.; Zvyaga, T.; Soars, M. G. Drug-induced perturbations of the bile acid pool, cholestasis, and hepatotoxicity: mechanistic considerations beyond the direct inhibition of the bile salt export pump. Drug Metab. Dispos., 2014, 42(4), 566-574.
29. Wu, C. Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res., 2005, 22(1), 11-23.
30. Shugarts, S.; Benet, L. Z. The role of transporters in the pharma cokinetics of orally administered drugs. Pharm. Res., 2009, 26(9), 2039-2054.
31. Benet, L. Z. The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J. Pharm. Sci., 2013, 102(1), 34-42.
32. Feng, B.; Hurst, S.; Lu, Y.; Varma, M. V.; Rotter, C. J.; El-Kattan, A.; Lockwood, P.; Corrigan, B. Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Mol. Pharm., 2013, 10(11), 4207-4215.
33. Morrissey, K. M.; Stocker, S. L.; Wittwer, M. B.; Xu, L.; Giacomini, K. M. Renal transporters in drug development. Annu. Rev. Pharmacol. Toxicol., 2013, 53, 503-529.
34. König, J.; Müller, F.; Fromm, M. F. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol. Rev., 2013, 65(3), 944-966.
35. Benet, L. Z.; Cummins, C. L. The drug efflux-metabolism alliance: biochemical aspects. Adv. Drug Deliv. Rev., 2001, 50(Suppl 1), S3-11.
36. Knight, B.; Troutman, M.; Thakker, D. R. Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge. Curr. Opin. Pharmacol., 2006, 6(5), 528-532.
37. Christians, U.; Schmitz, V.; Haschke, M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin. Drug Metab. Toxicol., 2005, 1(4), 641-654.
38. Englund, G.; Lundquist, P.; Skogastierna, C.; Johansson, J.; Hoogstraate, J.; Afzelius, L.; Andersson, TB.; Projean, D. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors. Drug Metab. Dispos., 2014, 42(3), 441-447.
39. Siissalo, S.; Heikkinen, A. T. In vitro methods to study the interplay of drug metabolism and efflux in the intestine. Curr. Drug Metab., 2013, 14(1), 102-111.
40. Cummins, C. L.; Jacobsen, W.; Christians, U.; Benet, L. Z. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther., 2004, 308(1), 143-155.
41. Cummins, C. L.; Salphati, L.; Reid, M. J.; Benet, L. Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther., 2003, 305(1), 306-314.
42. Badhan, R.; Penny, J.; Galetin, A.; Houston, J. B. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. J. Pharm. Sci., 2009, 98(6), 2180-2197.
43. Gertz, M.; Houston, J. B.; Galetin, A. Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab. Dispos., 2011, 39(9), 1633-1642.
44. Tam, D.; Sun, H.; Pang, K. S. Influence of P-glycoprotein.; transfer clearances.; and drug binding on intestinal metabolism in Caco-2 cell monolayers or membrane preparations: a theoretical analysis. Drug Metab. Dispos., 2003, 31(10), 1214-1226.
45. Gan, L. S.; Moseley, M. A.; Khosla, B.; Augustijns, P. F.; Bradshaw, T. P.; Hendren, R. W.; Thakker, D. R. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab. Dispos., 1996, 24(3), 344-349.
46. Dufek, M. B.; Knight, B. M.; Bridges, A. S.; Thakker, D. R. Pglycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism. Drug Metab. Dispos., 2013, 41(3), 642-650.
47. Wu, B. Pharmacokinetic interplay of phase II metabolism and transport: a theoretical study. J. Pharm. Sci., 2012, 101(1), 381-393.
48. Wu, B.; Dong, D.; Hu, M.; Zhang, S. Quantitative prediction of glucuronidation in humans using the in vitro-in vivo extrapolation approach. Curr. Top. Med. Chem., 2013, 13(11), 1343-1352.
49. Idkaidek, N. M. Interplay of biopharmaceutics, biopharmaceutics drug disposition and salivary excretion classification systems. Saudi. Pharm. J., 2014, 22(1), 79-81.
50. Larregieu, C. A.; Benet, L. Z. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol. Pharm., 2014, 11(4), 1335-1344.
51. Lau, Y. Y.; Huang, Y.; Frassetto, L.; Benet, L. Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther., 2007, 81(2), 194-204.
52. Zheng, H. X.; Huang, Y.; Frassetto, L. A.; Benet, L. Z. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther., 2009, 85(1), 78-85.
53. Meyer zu Schwabedissen, H. E.; Kim, R. B. Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol. Pharm., 2009, 6(6), 1644-1661.
54. Wen, X.; Donepudi, A, C.; Thomas, P. E.; Slitt, A. L.; King, R. S.; Aleksunes, L. M. Regulation of hepatic phase II metabolism in pregnant mice. J. Pharmacol. Exp. Ther., 2013, 344(1), 244-252.
55. Runge-Morris, M.; Kocarek, T. A.; Falany, C. N. Regulation of the cytosolic sulfotransferases by nuclear receptors. Drug Metab. Rev., 2013, 45(1), 15-33.
56. Urquhart, B. L.; Tirona, R. G.; Kim, R. B. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47(5), 566-578.
57. Aleksunes, L. M.; Klaassen, C. D. Coordinated regulation of hepatic phase I and II drug-metabolizing genes and transporters using AhR-, CAR-, PXR-, PPARγ-, and Nrf2-null mice. Drug Metab. Dispos., 2012, 40(7), 1366-1379.
58. Chai, X.; Zeng, S.; Xie, W. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin. Drug Metab. Toxicol., 2013, 9(3), 253-266.
59. Adachi, T.; Nakagawa, H.; Hagiya, Y.; Yasuoka, T.; Ishikawa, T. Transport-metabolism interplay: LXRalpha-mediated induction of human ABC transporter ABCC2 (cMOAT/MRP2) in HepG2 cells. Mol. Pharm., 2009, 6(6), 1678-1688.
60. Olinga, P.; Elferink, M. G.; Draaisma, A. L.; Merema, M. T.; Castell, J. V.; Pérez, G.; Groothuis, G. M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci., 2008, 33(4-5), 380-389.
61. Köhle, C.; Bock, K. W. Coordinate regulation of human drugmetabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol., 2009, 77(4), 689-699.
62. Backman, J. T.; Luurila, H.; Neuvonen, M.; Neuvonen, P. J. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther., 2005, 78(2), 154-167.
63. Shi, S.; Mörike, K.; Klotz, U. The clinical implications of ageing for rational drug therapy. Eur. J. Clin. Pharmacol., 2008, 64(2), 183-199.
64. Shi, S.; Klotz, U. Age-related changes in pharmacokinetics. Curr. Drug Metab., 2011, 12(7), 601-610.
65. Shi, S.; Klotz, U. Drug interactions with herbal medicines. Clin. Pharmacokinet., 2012, 51(2), 77-104.
66. Lalande, L.; Charpiat, B.; Leboucher, G.; Tod, M. Consequences of renal failure on non-renal clearance of drugs. Clin. Pharmacokinet., 2014, 53(6), 521-532.
67. Yeung, C. K.; Shen, D. D.; Thummel, K. E.; Himmelfarb, J. Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int., 2014, 85(3), 522-528.
68. Mudra, D. R.; Desino, K. E.; Desai, PV. In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp. Curr. Drug Metab., 2011, 12(8), 750-773.
69. Costa, A.; Sarmento, B.; Seabra, V. An evaluation of the latest in vitro tools for drug metabolism studies. Expert Opin. Drug Metab. Toxicol., 2014, 10(1), 103-119.
70. Volpe, D. A. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem., 2011, 3(16), 2063-2077.
71. Kuteykin-Teplyakov, K.; Luna-Tortós, C.; Ambroziak, K.; Löscher, W. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport. Br. J. Pharmacol., 2010, 160(6), 1453-1463.
72. Ahlin, G.; Hilgendorf C.; Karlsson J.; Szigyarto CA.; Uhlén M.; Artursson P. Endogenous gene and protein expression of drugtransporting proteins in cell lines routinely used in drug discovery programs. Drug Metab. Dispos., 2009, 37(12), 2275-2283.
73. Kwatra, D.; Budda, B.; Vadlapudi, A. D.; Vadlapatla, R. K.; Pal, D.; Mitra, A. K. Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism. Mol. Pharm., 2012, 9(7), 1877-1886.
74. Mouly, S. J.; Paine, M. F.; Watkins, P. B. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal firstpass extraction of saquinavir. J. Pharmacol. Exp. Ther., 2004, 308(3), 941-948.
75. Griffin, L.; Annaert, P.; Brouwer, K. L. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J. Pharm. Sci., 2011, 100(9), 3636-3654.
76. Swift, B.; Pfeifer, N. D.; Brouwer, K. L. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactionsand hepatotoxicity. Drug Metab. Rev., 2010, 42(3), 446-471.
77. Brown, H. S.; Wilby, A. J.; Alder, J.; Houston, J. B. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: transporter-enzyme interplay. Drug Metab. Dispos., 2010, 38(12), 2139-2146.
78. Li, Y.; Zhou, J.; Ramsden, D.; Taub, M. E.; O'Brien, D.; Xu, J.; Busacca, C. A.; Gonnella, N.; Tweedie, D. J. Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation. Drug Metab. Dispos., 2014, 42(3), 384-393.
79. Pelkonen, O.; Turpeinen, M.; Raunio, H. In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions. Clin. Pharmacokinet., 2011, 50(8), 483-491.
80. Gertz, M.; Harrison, A.; Houston, J. B.; Galetin, A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos., 2010, 38(7), 1147-1158.
81. Nishimuta, H.; Sato, K.; Yabuki, M.; Komuro, S. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab. Pharmacokinet., 2011, 26(6), 592-601.
82. Galetin, A. Rationalizing underprediction of drug clearance from enzyme and transporter kinetic data: from in vitro tools to mechanistic modeling. Methods Mol. Biol., 2014, 1113, 255-288.
83. Rabba, A. K.; Si, L.; Xue, K.; Li, M.; Li, G. In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay. J. Pharm. Pharm. Sci., 2011, 14(2), 138-147.
84. Wahajuddin.; Raju KS.; Singh SP.; Taneja I. Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Antimicrob. Agents Chemother., 2014, 58(1), 489-494.
85. Wu, C. Y.; Benet, L. Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab. Dispos., 2003, 31(11), 1292-1295.
86. Pfeifer, N. D.; Yang, K.; Brouwer, K. L. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes. J. Pharmacol. Exp. Ther., 2013, 347(3), 727-736.
87. Pfeifer, N. D.; Bridges, A. S.; Ferslew, B. C.; Hardwick, R. N.; Brouwer, K. L. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver. J. Pharmacol. Exp. Ther., 2013, 347(3), 737-745.
88. Nagar, S.; Tucker, J.; Weiskircher, E. A.; Bhoopathy, S.; Hidalgo, I. J.; Korzekwa, K. Compartmental models for apical efflux by Pglycoprotein-part 1: evaluation of model complexity. Pharm. Res., 2014, 31(2), 347-359.
89. Korzekwa, K.; Nagar, S. Compartmental models for apical efflux by P-glycoprotein: part 2 - a theoretical study on transporter kinetic parameters. Pharm. Res., 2014, 31(2), 335-346.
90. Jamei, M.; Bajot, F.; Neuhoff, S.; Barter, Z.; Yang, J.; Rostami-Hodjegan, A.; Rowland-Yeo, K. A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin. Pharmacokinet., 2014, 53(1), 73-87.
91. Darwich, A. S.; Neuhoff, S.; Jamei, M.; Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM) " model. Curr. Drug Metab., 2010, 11(9), 716-729.
92. Garmire, L. X.; Hunt, C. A. In silico methods for unraveling the mechanistic complexities of intestinal absorption: metabolismefflux transport interactions. Drug Metab. Dispos., 2008, 36(7), 1414-1424.
93. Jones, H.; Rowland-Yeo, K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT. Pharmacometrics Syst. Pharmacol., 2013, 2, e63.
94. Shi, S. Biologics: an update and challenge of their pharmacokinetics. Curr. Drug Metab., 2014, 15(3), 271-290.
95. Chow, E. C.; Pang, K. S. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr. Drug Metab., 2013, 14(1), 57-79.
96. Poggesi, I.; Snoeys, J.; Van Peer, A. The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement. Expert Opin. Drug Metab. Toxicol., 2014, 10(5), 631-635.
97. Zamek-Gliszczynski, M. J.; Lee, C. A.; Poirier, A.; Bentz, J.; Chu, X.; Ellens, H.; Ishikawa, T.; Jamei, M.; Kalvass, J. C.; Nagar, S.; Pang, K. S.; Korzekwa, K.; Swaan, P. W.; Taub, M. E.; Zhao, P.; Galetin, A; International Transporter Consortium. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clin. Pharmacol. Ther., 2013, 94(1), 64-79.
98. Sirianni, G. L.; Pang, K. S. Organ clearance concepts: new perspectives on old principles. J. Pharmacokinet. Biopharm., 1997, 25(4), 449-470.
99. Rostami-Hodjegan, A. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. Clin. Pharmacol. Ther., 2012, 92(1), 50-61.
100. Chen, Y.; Jin, J. Y.; Mukadam, S.; Malhi, V.; Kenny, J. R. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm. Drug Dispos., 2012, 33(2), 85-98.
101. Harwood, M. D.; Neuhoff, S.; Carlson, G. L.; Warhurst, G.; Rostami-Hodjegan, A. Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption. Biopharm. Drug Dispos., 2013, 34(1), 2-28.
102. Ball, K.; Bouzom, F.; Scherrmann, J. M.; Walther, B.; Declèves, X. Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier-towards a mechanistic IVIVEbased approach. AAPS. J., 2013, 15(4), 913-932.
103. Yoon, M.; Campbell, J. L.; Andersen, M. E.; Clewell, H. J. Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol., 2012, 42(8), 633-652.
104. Abuasal, B. S.; Bolger, M. B.; Walker, D. K.; Kaddoumi, A. In silico modeling for the nonlinear absorption kinetics of UK-343, 664: a P-gp and CYP3A4 substrate. Mol. Pharm., 2012, 9(3), 492-504.
105. van Waterschoot, R. A.; Lagas, J. S.; Wagenaar, E.; van der Kruijssen, C. M.; van Herwaarden, A. E.; Song, J. Y.; Rooswinkel, R. W.; van Tellingen, O.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res., 2009, 69(23), 8996-9002.
106. van Waterschoot, R. A.; Lagas, J. S.; Wagenaar, E.; Rosing, H.; Beijnen, J. H.; Schinkel, A. H. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int. J. Cancer., 2010, 127(12), 2959-2964.
107. Lagas, J. S.; Damen, C. W.; van Waterschoot, R. A.; Iusuf, D.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol. Pharmacol., 2012, 82(4), 636-644.
108. van Waterschoot, R. A.; ter Heine, R.; Wagenaar, E.; van der Kruijssen, C. M.; Rooswinkel, R. W.; Huitema, A. D.; Beijnen, J. H.; Schinkel, A. H. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir. Br. J. Pharmacol., 2010, 160(5), 1224-1233.
109. Hendrikx, J. J.; Lagas, J. S.; Rosing, H.; Schellens, J. H.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int. J. Cancer, 2013, 132(10), 2439-2447.
110. Dufek, M. B.; Bridges, A. S.; Thakker, D. R. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption. Drug Metab. Dispos., 2013, 41(9), 1695-1702.
111. Kurnik, D.; Wood, A. J.; Wilkinson, G. R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther., 2006, 80(3), 228-234.
112. Frassetto, L. A.; Poon, S.; Tsourounis, C.; Valera, C.; Benet, L. Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther., 2007, 81(6), 828-832.
113. Zanger, U. M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther., 2013, 138(1), 103-141.
114. Miksys, S.; Tyndale, R. F. Cytochrome P450-mediated drug metabolism in the brain. J. Psychiatry Neurosci., 2013, 38(3), 152-163.
115. Gundert-Remy, U.; Bernauer, U.; Blömeke, B.; Döring, B.; Fabian, E.; Goebel, C.; Hessel, S.; Jäckh, C.; Lampen, A.; Oesch, F.; Petzinger, E.; Völkel, W.; Roos, P. H. Extrahepatic metabolism at the body's internal-external interfaces. Drug Metab. Rev., 2014, 46(3), 291-324.
116. Knights, K. M.; Rowland, A.; Miners, J. O. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT). Br. J. Clin. Pharmacol., 2013, 76(4), 587-602.
117. Decleves, X.; Jacob, A.; Yousif, S.; Shawahna, R.; Potin, S.; Scherrmann, J. M. Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. Curr. Drug Metab., 2011, 12(8), 732-741.
118. Kodaira, H.; Kusuhara, H.; Ushiki, J.; Fuse, E.; Sugiyama, Y. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther., 2010, 333(3), 788-796.
119. Roth, M.; Obaidat, A.; Hagenbuch, B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br. J. Pharmacol., 2012, 165(5), 1260-1287.
120. Sprowl, J. A.; Sparreboom, A. Uptake carriers and oncology drug safety. Drug Metab. Dispos., 2014, 42(4), 611-622.
121. Fahrmayr, C.; Fromm, M. F.; König, J. Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects. Drug Metab. Rev., 2010, 42(3), 380-401.
122. Maeda, K.; Ikeda, Y.; Fujita, T.; Yoshida, K.; Azuma, Y.; Haruyama, Y.; Yamane, N.; Kumagai, Y.; Sugiyama, Y. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin. Pharmacol. Ther., 2011, 90(4), 575-581.
123. Varma, M. V.; Lin, J.; Bi, Y. A.; Rotter, C. J.; Fahmi, O. A.; Lam, J. L.; El-Kattan, A. F.; Goosen, T. C.; Lai, Y. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab. Dispos., 2013, 41(5), 966-974.
124. Varma, M. V.; Lai, Y.; Kimoto, E.; Goosen, T. C.; El-Kattan, A. F.; Kumar, V. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm. Res., 2013, 30(4), 1188-1199.
125. Niemi, M.; Pasanen, M. K.; Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev., 2011, 63(1), 157-181.
126. König, J. Uptake transporters of the human OATP family: molecular characteristics, substrates, their role in drug-drug interactions, and functional consequences of polymorphisms. Handb. Exp. Pharmacol., 2011, (201), 1-28.
127. Shitara, Y.; Maeda, K.; Ikejiri, K.; Yoshida, K.; Horie, T.; Sugiyama, Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm. Drug Dispos., 2013, 34(1), 45-78.
128. Nordell, P.; Winiwarter, S.; Hilgendorf, C. Resolving the distributionmetabolism interplay of eight OATP substrates in the standard clearance assay with suspended human cryopreserved hepatocytes. Mol. Pharm., 2013, 10(12), 4443-4451.
129. Lam, J. L.; Benet, L. Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos., 2004, 32(11), 1311-1316.
130. Niemi, M.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia, 2003, 46(3), 347-351.
131. Kudo, T.; Hisaka, A.; Sugiyama, Y.; Ito, K. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab. Dispos., 2013, 41(2), 362-371.
132. Säll, C.; Houston, J. B.; Galetin, A. A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug Metab. Dispos., 2012, 40(7), 1279-1289.
133. Gan, J.; Chen, W.; Shen, H.; Gao, L.; Hong, Y.; Tian, Y.; Li, W.; Zhang, Y.; Tang, Y.; Zhang, H.; Humphreys, W. G.; Rodrigues, A. D. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. Br. J. Clin. Pharmacol., 2010, 70(6), 870-880.
134. Bidstrup, T. B.; Stilling, N.; Damkier, P.; Scharling, B.; Thomsen, M. S.; Brøsen, K. Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol., 2004, 60(2), 109-114.
135. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther., 2006, 316(2), 762-771.
136. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos., 2006, 34(7), 1175-1181.
137. Ulvestad, M.; Skottheim, I. B.; Jakobsen, G. S.; Bremer, S.; Molden, E.; Asberg, A.; Hjelmesæth, J.; Andersson, T. B.; Sandbu, R.; Christensen, H. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin. Pharmacol. Ther., 2013, 93(3), 275-282.
138. Chang, J. H.; Ly, J.; Plise, E.; Zhang, X.; Messick, K.; Wright, M.; Cheong, J. Differential effects of rifampin and ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice. Drug Metab. Dispos., 2014, 42(6), 1067-1073.
139. Chu, X.; Cai, X.; Cui, D.; Tang, C.; Ghosal, A.; Chan, G.; Green, M. D.; Kuo, Y.; Liang, Y.; Maciolek, C. M.; Palamanda, J.; Evers, R.; Prueksaritanont, T. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab. Dispos., 2013, 41(3), 668-681.
140. Franke, R. M.; Baker, S. D.; Mathijssen, R. H.; Schuetz, E. G.; Sparreboom, A. Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. Clin. Pharmacol. Ther., 2008, 84(6), 704-709.
141. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo extrapolation of transportermediated clearance in the liver and kidney. Drug Metab. Pharmacokinet., 2009, 24(1), 37-52.
142. Döring, B.; Petzinger, E. Phase 0 and phase III transport in various organs: Combined concept of phases in xenobiotic transport and metabolism. Drug Metab. Rev., 2014, 46(3), 261-282.
143. Nies, A. T.; Schwab, M.; Keppler, D. Interplay of conjugating enzymes with OATP uptake transporters and ABCC/MRP efflux pumps in the elimination of drugs. Expert Opin. Drug Metab. Toxicol., 2008, 4(5), 545-568.
144. Neve, E. P.; Artursson, P.; Ingelman-Sundberg, M.; Karlgren, M. An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux. Mol. Pharm., 2013, 10(8), 3152-3163.
145. Fahrmayr, C.; König, J.; Auge, D.; Mieth, M.; Münch, K.; Segrestaa, J.; Pfeifer, T.; Treiber, A.; Fromm, M. Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKIIOATP1B1-CYP3A4-UGT1A1-MRP2 quadruple-transfected cell line. Br. J. Pharmacol., 2013, 169(1), 21-33.
146. Lau, Y. Y.; Wu, C. Y.; Okochi, H.; Benet, L. Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: heimpact patic enzyme-transporter interplay. J. Pharmacol. Exp. Ther., 2004, 308(3), 1040-1045.
147. Hobbs, M.; Parker, C.; Birch, H.; Kenworthy, K. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologicallybased pharmacokinetic model. Xenobiotica, 2012, 42(4), 327-338.
148. Gertz, M.; Cartwright, C. M.; Hobbs, M. J.; Kenworthy, K. E.; Rowland, M.; Houston, J. B.; Galetin, A. Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential. Pharm. Res., 2013, 30(3), 761-780.
149. Lam, J. L.; Okochi, H.; Huang, Y.; Benet, L. Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos., 2006, 34(8), 1336-1344.
150. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub., 2010, 154(2), 103-116.
151. Sim, S. C.; Kacevska, M.; Ingelman-Sundberg, M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J., 2013, 13(1), 1-11.
152. Zhang, M.; An, C.; Gao, Y.; Leak, R. K.; Chen, J.; Zhang, F. Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog. Neurobiol., 2013, 100, 30-47.
153. Zamek-Gliszczynski, M. J.; Hoffmaster, K. A.; Nezasa, K.; Tallman, M. N.; Brouwer, K. L. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 2006, 27(5), 447-486.
154. Wlcek, K.; Hofstetter, L.; Stieger, B. Transport of estradiol-17β-glucuronide, estrone-3-sulfate and taurocholate across the endoplasmic reticulum membrane: evidence for different transport systems. Biochem. Pharmacol., 2014, 88(1), 106-118.
155. Liu, Z.; Hu, M. Natural polyphenol disposition via coupled metabolic pathways. Expert Opin. Drug Metab. Toxicol., 2007, 3(3), 389-406.
156. Vaidya, S. S.; Walsh, S. W.; Gerk, P. M. Formation and efflux of ATP-binding cassette transporter substrate 2, 4-dinitrophenyl-Sglutathione from cultured human term placental villous tissue fragments. Mol. Pharm., 2009, 6(6), 1689-1702.
157. Xu, H.; Kulkarni, K. H.; Singh, R.; Yang, Z.; Wang, S. W.; Tam, V. H.; Hu, M. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol. Pharm., 2009, 6(6), 1703-1715.
158. Adachi, Y.; Suzuki, H.; Schinkel, A. H.; Sugiyama, Y. Role of breast cancer resistance protein (Bcrp1/Abcg2) in the extrusion of glucuronide and sulfate conjugates from enterocytes to intestinal lumen. Mol. Pharmacol., 2005, 67(3), 923-928.
159. Kosaka, K.; Sakai, N.; Endo, Y.; Fukuhara, Y.; Tsuda-Tsukimoto, M.; Ohtsuka, T.; Kino, I.; Tanimoto, T.; Takeba, N.; Takahashi, M.; Kume, T. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Drug Metab. Dispos., 2011, 39(9), 1495-1502.
160. Wei, Y.; Wu, B.; Jiang, W.; Yin, T.; Jia, X.; Basu, S.; Yang, G.; Hu, M. Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. Mol. Pharm., 2013, 10(5), 1736-1750.
161. Sun, H.; Zeng, Y. Y.; Pang, K. S. Interplay of phase II enzymes and transporters in futile cycling: influence of multidrug resistanceassociated protein 2-mediated excretion of estradiol 17beta-Dglucuronide and its 3-sulfate metabolite on net sulfation in perfused TR (-) and Wistar rat liver preparations. Drug Metab. Dispos., 2010, 38(5), 769-780.
162. Wu, B.; Kulkarni, K.; Basu, S.; Zhang, S.; Hu, M. First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics. J. Pharm, Sci., 2011, 100(9), 3655-3681.
163. Tripathi, S. P.; Bhadauriya, A.; Patil, A.; Sangamwar, A. T. Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Drug Metab. Rev., 2013, 45(2), 231-252.
164. Wittgen, H. G. The role of brain and intestinal efflux transporters in disposition of central nervous system drugs. (https://www.tipharma.com/fileadmin/user-upload/Theses/PDF/Ha nneke-Wittgen-T5-105.pdf.) (Accessed June 9, 2014)
165. Wittgen, H. G.; van den Heuvel, J. J.; van den Broek, P. H.; Siissalo, S.; Groothuis, G. M.; de Graaf, I. A.; Koenderink, J. B.; Russel, F. G. Transport of the coumarin metabolite 7-hydroxycoumarin glucuronide is mediated via multidrug resistance-associated proteins 3 and 4. Drug Metab. Dispos., 2012, 40(6), 1076-1079.
166. Zelcer, N.; van de Wetering, K.; Hillebrand, M.; Sarton, E.; Kuil, A.; Wielinga, P. R.; Tephly, T.; Dahan, A.; Beijnen, J. H.; Borst, P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. Proc. Natl. Acad. Sci. USA., 2005, 102(20), 7274-7279.
167. van de Wetering, K.; Zelcer, N.; Kuil, A.; Feddema, W.; Hillebrand, M.; Vlaming, M. L.; Schinkel, A. H.; Beijnen, J. H.; Borst, P. Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides. Mol. Pharmacol., 2007, 72(2), 387-394.
168. Jiang, W.; Hu, M. Mutual interactions between flavonoids and enzymatic and transporter elements responsible for flavonoid disposition via phase II metabolic pathways. RSC. Adv., 2012, 2, 7948-7963
169. Chen, Z.; Zheng, S.; Li, L.; Jiang, H. Metabolism of flavonoids in human: a comprehensive review. Curr. Drug Metab., 2014, 15(1), 48-61.
170. Jeong, E. J.; Liu, X.; Jia, X.; Chen, J.; Hu, M. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab., 2005, 6(5), 455-468.
171. Liu, W.; Feng, Q.; Li, Y.; Ye, L.; Hu, M.; Liu, Z. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. Toxicol. Appl. Pharmacol., 2012, 265(3), 316-324.
172. Mitra, P.; Audus, KL. MRP isoforms and BCRP mediate sulfate conjugate efflux out of BeWo cells. Int. J. Pharm., 2010, 384(1-2), 15-23.
173. Blazquez, AG.; Briz, O.; Gonzalez-Sanchez, E.; Perez, M. J.; Ghanem, C. I.; Marin, J. J. The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids during maternal cholestasis. Toxicol. Appl. Pharmacol., 2014, 277(1), 77-85.
174. Jiang, W.; Xu, B.; Wu, B.; Yu, R.; Hu, M. UDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP. Drug Metab. Dispos., 2012, 40(2), 336-345.
175. Wu, B.; Jiang, W.; Yin, T.; Gao, S.; Hu, M. A new strategy to rapidly evaluate kinetics of glucuronide efflux by breast cancer resistance protein (BCRP/ABCG2). Pharm. Res., 2012, 29(11), 3199-3208.
176. Tang, L.; Li, Y.; Chen, W. Y.; Zeng, S.; Dong, L. N.; Peng, X. J.; Jiang, W.; Hu, M.; Liu, Z. Q. Breast cancer resistance proteinmediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9. Pharm. Res., 2014, 31(4), 847-860.
177. Zhu, W.; Xu H.; Wang SW.; Hu M. Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine. AAPS. J., 2010, 12(4), 525-536.
178. Enokizono, J.; Kusuhara, H.; Sugiyama, Y. Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol., 2007, 72(4), 967-975.
179. Álvarez, A. I.; Vallejo, F.; Barrera, B.; Merino, G.; Prieto, J. G.; Tomás-Barberán, F.; Espín, J. C. Bioavailability of the glucuronide and sulfate conjugates of genistein and daidzein in breast cancer resistance protein 1 knockout mice. Drug Metab. Dispos., 2011, 39(11), 2008-2012.
180. Alvarez, A. I.; Vallejo, F.; Barrera, B.; Merino, G.; Prieto, J. G.; Tomás-Barberán, F.; Espín, J. C. Reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab. Dispos., 2012, 40(11), 2219; author reply 2219-2220.
181. Yang, Z.; Zhu, W.; Gao, S.; Yin, T.; Jiang, W.; Hu, M. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab. Dispos., 2012, 40(10), 1883-1893.
182. Fahrmayr, C.; König, J.; Auge, D.; Mieth, M.; Fromm, M. F. Identi fication of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCKOATP1B1-UGT1A1-MRP2 cells. Br. J. Pharmacol., 2012, 165(6), 1836-1847.
183. Yiannakopoulou, ECh. Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications. Pharmacogenomics J., 2013, 13(2), 105-109.
184. Umamaheswaran, G.; Kumar, DK.; Adithan, C. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian J. Med. Res., 2014, 139(1), 27-65.
185. ∗10. Br. J. Pharmacol., 2011, 164(2b), 433-443.
186. Yoo, H. D.; Cho, H. Y.; Lee, S. N.; Yoon, H.; Lee, Y. B. Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. J. Pharmacokinet. Pharmacodyn., 2012, 39(4), 329-341.
187. Suzuki, Y.; Tsuneyama, N.; Fukui, N.; Sugai, T.; Watanabe, J.; Ono, S.; Saito, M.; Someya, T. Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia. J. Clin. Psychopharmacol., 2013, 33(3), 411-414.
188. Gong, I. Y.; Kim, R. B. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab. Pharmacokinet., 2013, 28(1), 4-18.
189. Nakanishi, T.; Tamai, I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab. Pharmacokinet., 2012, 27(1), 106-121.
190. Nies, A. T.; Niemi, M.; Burk, O.; Winter, S.; Zanger, U. M.; Stieger, B.; Schwab, M.; Schaeffeler, E. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med., 2013, 5(1), 1.
191. Carr, D. F.; O'Meara, H.; Jorgensen, A. L.; Campbell, J.; Hobbs, M.; McCann, G.; van Staa, T.; Pirmohamed, M. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-ofconcept study using the clinical practice research datalink. Clin. Pharmacol. Ther., 2013, 94(6), 695-701.
192. Stewart, A. SLCO1B1 Polymorphisms and statin-induced myopathy. PLoS. Curr., 2013, Dec. 4, 5.
193. SEARCH Collaborative Group.; Link, E.; Parish, S.; Armitage, J.; Bowman, L.; Heath, S.; Matsuda, F.; Gut, I.; Lathrop, M.; Collins, R. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N. Engl. J. Med., 2008, 359(8), 789-799.
194. Sadee, W. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. J. Pharm. Sci., 2013, 102(9), 2924-2929.
195. Kalliokoski, A.; Neuvonen, P. J.; Niemi, M. SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin. Pharmacol. Toxicol., 2010, 107(4), 775-781.
196. Tomalik-Scharte, D.; Fuhr, U.; Hellmich, M.; Frank, D.; Doroshyenko, O.; Jetter, A.; Stingl, J. C. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab. Dispos., 2011, 39(5), 927-932.
197. Niemi, M.; Leathart, J. B.; Neuvonen, M.; Backman, J. T.; Daly, A. K.; Neuvonen, P. J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin. Pharmacol. Ther., 2003, 74(4), 380-387.
198. Gertz, M.; Tsamandouras, N.; Säll, C.; Houston, J. B.; Galetin, A. Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. Pharm. Res., 2014, 31(9):2367-2382.
199. Yoo, H. D.; Lee, Y. B. Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. Arch. Pharm. Res., 2011, 34(11), 1817-1828.
200. Varma, M. V.; Scialis, R. J.; Lin, J.; Bi, Y. A.; Rotter, C. J.; Goosen, T. C.; Yang, X. Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J., 2014, 16(4), 736-748.
201. Al-Khazaali, A.1.; Arora, R. P-glycoprotein: a focus on characterizing variability in cardiovascular pharmacotherapeutics. Am. J. Ther., 2014, 21(1), 2-9.
202. Yang, K.; Brouwer, K. L. Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion. Drug Metab. Dispos., 2014, 42(7), 1219-1226.
203. Wahajuddin.; Taneja, I.; Arora, S.; Raju, K. S.; Siddiqui, N. Disposition of pharmacologically active dietary isoflavones in biological systems. Curr. Drug Metab., 2013, 14(4), 369-380.
204. Ramsden, D.; Tweedie, D. J.; Chan, T. S.; Taub, M. E.; Li, Y. Bridging in vitro and in vivo metabolism and transport of faldaprevir in human using a novel cocultured human hepatocyte system, HepatoPac. Drug Metab. Dispos., 2014, 42(3), 394-406.
205. Ramsden, D.; Tweedie, D. J.; St George, R.; Chen, L. Z.; Li, Y. Generating an in vitro-in vivo correlation for metabolism and liver enrichment of a hepatitis C virus drug, faldaprevir, using a rat hepatocyte model (HepatoPac). Drug Metab. Dispos., 2014, 42(3), 407-414.
206. Benet, L. Z. A step closer to personalized chemotherapy: consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates. Clin. Pharmacol. Ther., 2012, 92(5), 551-552.